SEED in
the Spotlight

SEED Therapeutics Doses First Patient in Phase 1 Trial of ST-01156, a Molecular Glue Degrader Targeting RBM39

Corporate Presentation: Transforming Undruggable Targets into Therapeutics

SEED Therapeutics Receives IND Clearance from China’s NMPA for ST-01156

Nature: Protein degraders push into novel target space

SEED Therapeutics Completes $30 Million Series A-3 Financing

20 Years of the Ubiquitin Revolution: Honoring Nobel Laureate Professor Avram Hershko and the Future of Targeted Protein Degradation

SEED Therapeutics Named Finalist for 2025 Prix Galien USA “Best Start-Up” Award

FDA Clears IND for SEED Therapeutics’ RBM39 Degrader ST-01156

SEED Therapeutics Appoints Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer

SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025

American Association for Cancer Research 2025 Poster – Targeting Ewing Sarcoma with A Novel RBM39 Degrader

SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago

SEED AACR 2025 Presentation: Liu F. et al. Targeting Ewing Sarcoma with A Novel RBM39 Degrader: DNA Damage Repair Pathway Effects (Abstract 1556)

RBM39 Functions as a Potential Oncogene Through the NF-κB Signaling Pathway in Colorectal Cancer Cells

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors

Protein degraders push into novel target space

SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors

SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications

The glue degraders

SEED Therapeutics is Featured Prominently in a Molecular Glue Development Publication, Nature Biotechnology

Nature Biotechnology Publication, March 2024

2023 TPD Think Tank Symposium

SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium

SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors Former Eisai Board Member

Seed Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors

Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma

Molecular glue binds protein degradation experts together

Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker

Seed Therapeutics has completed construction of a new state of the art innovation and research center at 411 Swedeland Road in King of Prussia, Pennsylvania

Defining molecular glues with a dual-nanobody cannabidiol sensor

BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly

BeyondSpring Creates Subsidiary, Seed Therapeutics, to Focus on Protein Degradation Platform

Mechanism of auxin perception by the TIR1 ubiquitin ligase

Structure of the Cul1–Rbx1–Skp1–F boxSkp2 SCF ubiquitin ligase complex

Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade

Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor

Proposed role of ATP in protein breakdown: Conjugation of proteins with multiple chains of the polypeptide of ATP-dependent proteolysis